Encephalopathy autoimmune evaluation, serum

Alphabetical Test listing

Encephalopathy autoimmune evaluation, serum-12690

  
Encephalopathy autoimmune evaluation, serum
  
12690
  
LAB12690
  
ENS2
  
ACh Receptor (muscle) binding Ab
AChR ganglionic Ab
AMPA-R Ab CBA
Amphiphysin Ab
Anti-Neuronal Nuclear Ab
Paraneoplastic
  
  • AMPA-R Ab CBA, S
  • Amphiphysin Ab, S
  • Anti-Glial Nuclear Ab, Type 1
  • Anti-Neuronal Nuclear Ab, Type 1
  • Anti-Neuronal Nuclear Ab, Type 2
  • Anti-Neuronal Nuclear Ab, Type 3
  • CASPR2-IgG CBA, S
  • CRMP-5-IgG, S
  • DPPX Ab IFA, S
  • Encephalopathy, Interpretation, S
  • GABA-B-R Ab CBA, S
  • GAD65 Ab Assay, S
  • GFAP IFA, S
  • IgLON5 IFA, S
  • LGI1-IgG CBA, S
  • mGluR1 Ab IFA, S
  • NIF IFA, S
  • Purkinje Cell Cytoplasmic Ab Type 1
  • Purkinje Cell Cytoplasmic Ab Type 2
  • Purkinje Cell Cytoplasmic Ab Type Tr
  
  • Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in serum specimens.

    The following accompaniments should increase of suspicion for autoimmune encephalopathy:
    • Headache
    • Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
    • History of cancer
    • Smoking history (20+ pack years) or other cancer risk factors
    • Inflammatory cerebral spinal fluid (or isolated protein elevation)
    • Neuroimaging signs suggesting inflammation
  • Evaluating limbic encephalitis (noninfectious)
  • Directing a focused search for cancer
  • Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect
  
  • For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication.
  • This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains.
  • Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.
  
Serum
  
  
4.0 mL
  
2.5 mL
  

Spin and separate

  
  
  

Spin

  

Refrigerated (preferred) - 28 days

Frozen - 28 days

Ambient - 72 hours

  
Mayo Clinic Laboratories (ENS2): R-MM
  
Varies
  
10 - 13 days
  

Indirect Immunofluorescence Assay (IFA), Cell Binding Assay (CBA), Live cell assay (LCA), Western blot (WB) and Radioimmunoassay (RIA).

  
86255 x 19
86341

Additional CPT codes (if appropriate):
83519 x 2
84182 x 7
86255 x 7
86256 x 8
  
11/18/2014
  
07/16/2021
  
05/11/2021